



# Clinical Efficacy of Intra-Articular Injections of Autologous Conditioned Serum Compared with Dexamethasone for The Treatment of Bilateral Knee Osteoarthritis. A Retrospective Analysis

Nicole N Hang<sup>1</sup>, Julio Reinecke<sup>2\*</sup>, Jeff C Lai<sup>3</sup> and David W Hang<sup>4</sup>

<sup>1</sup>Spine Center, University of Southern California Keck School of Medicine, USA

<sup>2</sup>Wehling & Partner, Düsseldorf, Germany

<sup>3</sup>Department of Family Medicine, Long Beach Memorial Primary Care Sports Medicine, University of California at Irvine, Long Beach, California, United States of America

<sup>4</sup>Shin Kong Orthopedic Sports Medicine Institute, Taipei, Taiwan

\*Corresponding author: Julio Reinecke, Wehling & Partner, Düsseldorf, Kasernenstr 1b, D-40213 Düsseldorf, Germany

Received: 📅 March 13, 2023

Published: 📅 March 24, 2023

## Abstract

**Objective:** Comparison of two effective intra-articular injection therapies, autologous conditioned serum versus dexamethasone in patients with chronic bilateral knee osteoarthritis.

**Methods:** In a monocentric closed cohort study with relocated baseline and an internal intra-individual matched comparison of the left and right knee, 34 patients (n = 68 knees) with knee osteoarthritis grade I-III were included in the analysis. Clinical scores were analyzed before intra-articular injection and at control visits. All patients received a series of six 2mL intra-articular injections with ACS into one knee over three weeks. All patients received one 5mg Dexamethasone injection in the contralateral knee. Both treatments are clinical routine and efficacious. Efficacy for each knee was measured by NRS pain score, WOMAC index and GPA questionnaires.

**Results:** Improvements of NRS, WOMAC global, WOMAC pain, WOMAC stiffness, WOMAC function at 3, 6, 12 months were statistically significant in favor of the ACS treated knees. GPA assessment also favored ACS vs Dexamethasone. Adverse events were recorded and are reported herein.

**Conclusion:** ACS is statistically significant superior to Dexamethasone. Both treatments are safe. Both ACS and Dexamethasone injection treatments significantly improve knee osteoarthritis pain, stiffness and function.

## Introduction

### Background/rationale

The irreversible, progressive and chronic nature of osteoarthritis (OA), at present, requires chronic management adjusted to the patient's individual needs. Currently approved treatment options are largely palliative, suppressing pain until joint replacement is judged to be unavoidable. There is consensus that

early surgery may not contribute to better outcomes [1]. According to OARSI and multiple Cochrane Reviews, the spectrum of currently available treatments is not only limited but lacks appropriate long-term efficacy (e.g. NSAIDs have low Effect Size d [104]. of 0.37 and safety issues) [2-4]. Also, decision-making has entered a phase that endeavors to include patient's opinion, reflecting a desire to reach more generalized acceptance e.g. in Rheumatoid Arthritis

[5]. Similar activities may ensue for OA given the growing medical need. Inflammatory cytokines are seen to be among key drivers in OA cartilage destruction or rheumatoid arthritis [5,6]. Further key factors in OA pathology include, but are not limited to, oxidative stress leading to higher concentrations of oxygen and nitrogen radicals which drive inflammation and impair joint homeostasis [7,8]. Chronic ATP deficiency due to mitochondrial dysfunction is part of this condition [9]. Interleukin-1 (IL-1), is one of the key mediators of cartilage destruction, stimulating proteolytic enzyme synthesis and attracting inflammatory cells to the joint and causing hyperalgesia [10]. Interleukin-1 receptor antagonist (IL-1Ra) is a natural competitive inhibitor of IL-1 and has been introduced to the market as recombinant IL-1Ra (Anakinra) for the treatment of rheumatoid or other inflammatory pathologies [11].

Gene therapy approaches utilizing the IL-1Ra gene have also been performed and are still experimental [1-11]. An alternative technique to generate IL-1Ra was published by Meijer et al. generating whole blood serum containing high concentrations of autologous IL-1Ra, Autologous Conditioned Serum (ACS) [12]. Publications have also used the terms "autologous IL-1Ra", "Orthokine", "Blood Clot Secretome" or "Blood Cell Secretome" for ACS [13]. This method stimulates autologous cytokine production by whole blood cells in addition to release to saturation of growth factors from platelets. ACS is re-injected into the osteoarthritic joint and other pathologies for pain and functional improvement [14].

ACS contains a plethora of components such as growth factors, cytokines, mitochondria derived peptides, alarmins, lipid mediators, exosomes, and potential radical scavengers [14-16]. It is now interpreted as, or containing a, whole blood secretome. ACS has been studied over more than two decades. The use of ACS has successfully expanded from the treatment of OA and radiculopathy to soft tissue disease (tendon, ligament, muscle injuries and meniscal injuries) and wound treatment [13,14,17-49]. It is now known that local injections with ACS have pain resolving and regenerative properties.

Glucocorticoid injection is among the most popular intra-articular therapies for OA due to its fast action and the lack of serious side effects [50]. Dexamethasone is one well established proponent drug that is known for its high potency. It is generally accepted that the beneficial effect of intra-articular glucocorticoid injection is immediate but short-lived and is more effective in cases with an inflammatory component [51]. Too frequent use is however frowned upon. OARSI recommendations in 2019 state: Intra-articular glucocorticoids (IACS) are conditionally recommended for acute (1-2 weeks) and short-term (4-6 weeks) pain relief [52].

## Objectives

In our clinical experience, glucocorticoid treatment and ACS treatment are equivalent therapeutic approaches. We therefore offer both therapeutic approaches to our patients and inform them about the advantages and disadvantages of both therapies. In some cases of bilateral OA, patients were unable to make a choice

between the two therapies. Therefore, in order to allow the patient to make a direct comparison and thus make the best individual treatment decision at subsequent treatments, we have chosen the approach of treating one knee joint with glucocorticoids and the other knee joint with ACS.

As this approach is rather unusual in daily medical practice, we decided to structure this information from our medical records and present it to the public.

## Methods

### Study design

Monocentric, closed cohort study with relocated baseline and an internal intra-individual matched comparison of left and right knee in a group of 34 patients.

### Setting

The treatments were executed at the Shin Kong Orthopedic Sports Medicine Centre of Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan, between 2005 and 2006. The observation period was 12 months. Post-examinations were performed after 3, 6 and 12 months. At the initial office visit, thorough and detailed explanation of the procedure, risks, complications, side effects, and potential therapeutic effects were given. The patient's medical history, physical examination, standing X-ray (AP, lateral, and merchant views) were documented in detail. Knee x-rays were evaluated according to the classification of Kellgren and Lawrence (KL) at the time of evaluation.<sup>63</sup> In order to obtain a higher objectification of their individual assessment of their symptoms, patients then completed our standard clinical efficacy symptom assessment questionnaires before the intra-articular injections and at each control visit for their respective knee joints.

All 34 patients were injected with ACS in one knee and Dexamethasone in the contralateral knee. For ACS preparation they donated 50 mL of blood into an approved medical device containing medical grade glass spheres (Orthokine® II Set 60 ml, Orthogen, Germany). These medical grade glass spheres are specifically polished, washed and otherwise untreated. They accelerate coagulation. The syringe containing the patient's whole blood was submitted to extended coagulation at 37°C for 24 hours. After extended coagulation, the ACS was recovered by centrifugation and then stored frozen in aliquots at -20°C until injection. Each patient's knees received either (1) a series of 6 (2mL each) injections with ACS twice per week over a three-week period into one knee or (2) a single dose of Dexamethasone-21-Phosphate Disodium 5mg (combined with 1mL of 2 % Xylocaine) into the contralateral knee. Knees were randomly assigned to the respective treatments. ACS treatment regimen was performed as was shown to be successful by Baltzer, et al. and Yang, et al. [27,29]. Each ACS injection was carried out with the use of AcroMed® 0.2 µm/3.2 cm filter (Pall Life Science, Ann Arbor, Michigan, USA).

### Participants

The cohort of patients who received ACS in one knee and Dexamethasone in the other knee.

in the contralateral knee was selected for analysis according to the following selection criteria: Male and female patients aged at least 21 years with radiographically documented bilateral osteoarthritic joints (K&L grade I - III), who had not undergone surgery three months prior to treatment and who had not received any additional anti-inflammatory drugs, intra-articular injections or surgical procedures prior to treatment. None of the patients had systemic disease of the musculoskeletal system (i.e., RA or gout), bone cancer, metastasis or tumor-like lesions of the knee, fixed lower limb deformities, history of bleeding disorders or current anticoagulant treatment, presence of hepatitis B or C, HIV 1 and 2 (AIDS virus), syphilis and HTLV I and II or acute infection of the knee. Patients had free access to a daily knee exercise programme, hydrotherapy, physiotherapy, the use of cryotherapy, the use of orthotics, the use of a cane or the use of acetaminophen.

### Data sources / Measurements

The investigation was based on our standard clinical efficacy symptom assessment questionnaires patients were asked to complete for their respective knee joints. These questionnaires consist of a numeric rating scale (NRS: 0-10) for pain, Western Ontario and McMaster Universities Arthritis Index (WOMAC scoring by NRS 0-10) and a Global Patient Assessment (GPA) questionnaire. GPA1: "How would you assess the effectiveness of your osteoarthritis treatment at the present time?" answers we given as "poor, unsatisfactory, satisfactory, sufficient, good and very good". GPA2: "How much has the therapy helped your disease?" answers were given in per cent. For NRS pain (Question: "What was your maximum pain in the past two weeks") and WOMAC lower values indicate improved symptoms. An independent third party performed the data input and analysis.

### Bias

Bilateral investigations have been criticized but also have been used in clinical and animal OA studies [53-62]. In the presented setting one of the main advantages is that the patient can directly compare the clinical changes in both knees and choose their own therapy for subsequent treatments. However, this advantage also implies the risk of a very individual ability to differentiate symptoms between the two knee joints and carries the risk of information bias, which cannot be excluded. Another risk is that, due to the lack of randomised allocation of therapy, a more severely affected knee may have been more likely to receive a particular therapy, leading to differential (non-random) misclassification. Nevertheless, an important advantage of this methodological approach is that the risk of common types of bias, such as selection, detection or recall bias, is not necessarily anticipated.

### Study Size

The study size of 34 subjects represents the total number of patients over a two-year period who meet the selection criteria for analysis. This may seem too small, but the intra-individual matching reduces the variability in the statistical analysis, which in turn leads to a more precise statement about the effects.

### Statistics

Statistical analysis was performed using descriptive methods and inferential analysis using appropriate significance tests. Missing values were not imputed. A two-tailed t-test for paired data was used to calculate probabilities for continuous data. A local p-value  $\leq 0.05$  was considered statistically significant [64].

Results were interpreted in a confirmatory manner. Statistical analysis was performed with SPSS version 24.0.

### Results

#### Participants

During the 2-year period, a total of 35 patients were eligible and screened for eligibility. One patient did not meet the selection criteria, so 34 were considered eligible and included in the study. All of them passed the control visit and were included in the analysis.

#### Descriptive data

Characteristics of study participants are displayed in Table 1.

### Main Results

WOMAC global improvement of 36% was defined to be clinically relevant. It was reached for DEXA treated knees at month 12 and for ACS treated knees at months 3, 6 and 12 (Table 2). ACS and DEXA baseline scores were statistically significantly different for NRS ( $p=0.01$ ) and WOMAC pain and global ( $p=0.015$ ;  $p=0.017$ ). ACS started off with worse baseline than DEXA and showed WOMAC global intra group effect sizes. 1.28, 1.32 and 1.4 at 3, 6 and 12 months respectively. DEXA showed intra group effect sizes of 0.47, 0.66 and 0.7 at 3, 6 and 12 months respectively (Table 3). A graphic display of the evolution of NRS graded pain (Figure 1) and the evolution of WOMAC global score (Figure 2) over time shows that both groups appear to benefit from the respective injection treatment. Both ACS and DEXA treated knees experienced statistically significant intra-group improvement of symptoms at 3, 6 and 12 months by NRS, WOMAC (Tables 3 & 4) and GPA (Figures 3 & 4). ACS treated knees performed significantly superior to DEXA at all follow-up evaluations. Matzkin et al. published a (rather high) 21.7% WOMAC global improvement vs baseline as the minimal clinically important difference (MCID) cutoff in a trial evaluating the efficacy of 1 mL of triamcinolone 10 mg and 4 mL of 1% lidocaine until 6 months follow up [105]. Table 4 shows that both groups in the present study fulfill this criterion at all follow up time points.

By GPA, over all follow ups of ACS knees, 55.9% of the patients rated the treatment as good to very good, 32.4% as sufficient to satisfactory, and 11.8% as poor or unsatisfactory. 64.7% of patients had 60 to 100% improvement in their disease, 17.6% had 20 to 60% improvement, and 17.6% had almost no improvement. Of the DEXA knees, 26.5% of the patients rated the treatment as good to very good, 58.8% as sufficient to satisfactory, and 14.7% as poor or unsatisfactory. 35.3% of patients rated the DEXA treated knees with 60 to 100% improvement in their disease, 38.2% with 20 to 60% improvement, and 26.5% with almost no improvement. No serious complications were observed (Table 4). The adverse events

did not have clinical impact; all side effects were mild and resolved spontaneously within a few hours (minor swelling, discomfort, soreness, mild pain, stiffness, and knee pain). Pain at injection

site was the most frequent adverse effect in the ACS (1.96% of interventions) knees. Soreness at injection site (14.71%) was most frequent adverse effect in the Dexta interventions.

**Table 1:** Characteristics of study participants.

|                   | N (%)             |
|-------------------|-------------------|
| Total patients    | 34 (100%)         |
| Total knees       | 68 (100%)         |
| Male              | 11 (32%)          |
| Female            | 23 (68%)          |
| OA (K&L grade)    |                   |
| K&L grade I       | 19 (56%)          |
| K&L grade II      | 6 (18%)           |
| K&L grade III     | 9 (26%)           |
| Mean (min-max)    |                   |
| Age (years)       | 61.3 (36 - 79)    |
| Height (cm)       | 162.1 (148 - 184) |
| Weight (kg)       | 67.8 (44 - 144)   |
| Symptoms (months) | 72.9 (4 - 240)    |

**Table 2:** Clinical responses between baseline and months 3, 6 and 12 for patients treated with ACS or Dexta. In both groups, the clinical responses were significantly improved after 3 months and the improvement continued at 6 and 12 months. Percentage of improvement is given. ACS meets the predefined score improvement of 36% (as a measure of therapeutic success) for all parameters and time points. Dexta meets the predefined score improvement for parameters NRS at 12 months, WOMAC stiffness at 6 and 12 months and for WOMAC function at 12 months.


| Table 2. Changes in clinical responses between baseline and 3, 6, 12 months by treatment groups |                      |         |                      |         |                       |         |
|-------------------------------------------------------------------------------------------------|----------------------|---------|----------------------|---------|-----------------------|---------|
|                                                                                                 | Baseline to 3 months |         | Baseline to 6 months |         | Baseline to 12 months |         |
| ACS                                                                                             | Mean $\pm$ SD        | p-value | Mean $\pm$ SD        | p-value | Mean $\pm$ SD         | p-value |
| NRS                                                                                             | -3.8 $\pm$ 2.7       | <.001   | -3.6 $\pm$ 2.5       | <.001   | -3.8 $\pm$ 2.2        | <.001   |
| % change                                                                                        | -59.4%               |         | -56.3%               |         | -57.8%                |         |
| WOMAC pain                                                                                      | -12.1 $\pm$ 8.6      | <.001   | -12.6 $\pm$ 8.2      | <.001   | -12.6 $\pm$ 10.0      | <.001   |
| % change                                                                                        | -56.5%               |         | -58.8%               |         | -58.3%                |         |
| WOMAC stiffness                                                                                 | -5.4 $\pm$ 5.3       | <.001   | -6.0 $\pm$ 5.0       | <.001   | -6.3 $\pm$ 6.8        | <.001   |
| % change                                                                                        | -58.1%               |         | -64.5%               |         | -67.7%                |         |
| WOMAC function                                                                                  | -41.0 $\pm$ 37.2     | <.001   | -43.6 $\pm$ 33.7     | <.001   | -47.1 $\pm$ 37.7      | <.001   |
| % change                                                                                        | -55.6%               |         | -59.1%               |         | -63.8%                |         |
| Dexta                                                                                           | Mean $\pm$ SD        | p-value | Mean $\pm$ SD        | p-value | Mean $\pm$ SD         | p-value |
| NRS                                                                                             | -1.2 $\pm$ 1.1       | <.001   | -2.0 $\pm$ 2.5       | <.001   | -2.2 $\pm$ 2.3        | <.001   |
| % change                                                                                        | -22.0%               |         | -35.6%               |         | -39.0%                |         |
| WOMAC pain                                                                                      | -4.2 $\pm$ 6.5       | <.001   | -6.1 $\pm$ 7.6       | <.001   | -6.6 $\pm$ 9.6        | <.001   |
| % change                                                                                        | -23.5%               |         | -31.1%               |         | -32.7%                |         |
| WOMAC stiffness                                                                                 | -2.7 $\pm$ 3.9       | <.001   | -3.7 $\pm$ 5.4       | <.001   | -4.1 $\pm$ 6.0        | <.001   |
| % change                                                                                        | -30.3%               |         | -39.3%               |         | -43.8%                |         |
| WOMAC function                                                                                  | -17.6 $\pm$ 26.1     | <.001   | -24.1 $\pm$ 33.0     | <.001   | -27.4 $\pm$ 35.7      | <.001   |
| % change                                                                                        | -25.6%               |         | -32.6%               |         | -37.5%                |         |

**Table 3:** Differences between ACS and Dexta treatment groups at 3, 6 and 12 months (NRS, WOMAC global, WOMAC pain, WOMAC stiffness, WOMAC function) were significantly better for ACS. Effect size (ES, Cohen's [104].) vs baseline is shown for WOMAC global with medium values for Dexta and large values for ACS. Percentage of improvement at follow ups is given for WOMAC global. Effect sizes [104] between groups are 0.62, 0.49 and 0.45 in favor of ACS at 3, 6 and 12 months.


| Table 5. Mean clinical scores at baseline, 3, 6 and 12 months for knees treated with ACS or Dexta |                        |                  |                                    |                                      |                                     |
|---------------------------------------------------------------------------------------------------|------------------------|------------------|------------------------------------|--------------------------------------|-------------------------------------|
|                                                                                                   |                        | Baseline         | Month 3                            | Month 6                              | Month 12                            |
|                                                                                                   |                        | Mean $\pm$ SD    | Mean $\pm$ SD                      | Mean $\pm$ SD                        | Mean $\pm$ SD                       |
| NRS                                                                                               | ACS                    | 6.4 $\pm$ 2.4    | 2.6 $\pm$ 2.1                      | 2.8 $\pm$ 2.2                        | 2.7 $\pm$ 1.9                       |
|                                                                                                   | Dexta                  | 5.8 $\pm$ 2.7    | 4.6 $\pm$ 2.3                      | 3.8 $\pm$ 2.0                        | 3.6 $\pm$ 1.9                       |
|                                                                                                   | p-value                | =0.01            | <0.001                             | =0.009                               | =0.029                              |
| WOMAC global<br>[0-240]                                                                           | ACS                    | 104.7 $\pm$ 51.2 | 46.1 $\pm$ 39.2<br>-55%<br>ES 1.28 | 42.5 $\pm$ 42.3<br>-59.4%<br>ES 1.32 | 38.7 $\pm$ 42.1<br>-63.0%<br>ES 1.4 |
|                                                                                                   | Dexta                  | 98.7 $\pm$ 53.7  | 74.1 $\pm$ 50.5<br>-25%<br>ES 0.47 | 64.7 $\pm$ 48.7<br>-34.4%<br>ES 0.66 | 60.6 $\pm$ 54.5<br>-38.6%<br>ES 0.7 |
|                                                                                                   | inter group comparison | =0.017           | <0.001<br>ES 0.62                  | <0.006<br>ES 0.49                    | <0.001<br>ES 0.45                   |
| WOMAC pain<br>[0-50]                                                                              | ACS                    | 21.6 $\pm$ 10.5  | 9.4 $\pm$ 2.1                      | 8.9 $\pm$ 9.0                        | 9.0 $\pm$ 10.4                      |
|                                                                                                   | Dexta                  | 19.3 $\pm$ 11.3  | 15.1 $\pm$ 8.5                     | 13.1 $\pm$ 9.2                       | 12.7 $\pm$ 10.5                     |
|                                                                                                   | p-value                | =0.015           | <0.001                             | =0.006                               | =0.019                              |
| WOMAC stiffness<br>[0-20]                                                                         | ACS                    | 9.3 $\pm$ 6.2    | 3.9 $\pm$ 4.6                      | 3.3 $\pm$ 3.8                        | 3.0 $\pm$ 3.5                       |
|                                                                                                   | Dexta                  | 9.1 $\pm$ 6.3    | 6.4 $\pm$ 5.5                      | 5.4 $\pm$ 4.3                        | 4.9 $\pm$ 4.5                       |
|                                                                                                   | p-value                | =0.263           | <0.001                             | =0.005                               | =0.003                              |
| WOMAC function<br>[0-170]                                                                         | ACS                    | 73.8 $\pm$ 37.2  | 32.8 $\pm$ 27.5                    | 30.2 $\pm$ 30.4                      | 26.7 $\pm$ 29.0                     |
|                                                                                                   | Dexta                  | 70.3 $\pm$ 39.2  | 52.7 $\pm$ 38.3                    | 46.2 $\pm$ 36.7                      | 42.9 $\pm$ 40.3                     |
|                                                                                                   | p-value                | =0.053           | <0.001                             | =0.009                               | <0.001                              |

**Table 4:** Frequency of adverse events in ACS and Dexta treatment as per number of injections. All events were classified as "mild".


|                              | Dexta |       | ACS |      |
|------------------------------|-------|-------|-----|------|
|                              | N     | %     | N   | %    |
| Number of injections         | 34    | 100   | 204 | 100  |
| Adverse events               |       |       |     |      |
| Mild swelling                | 1     | 2.94  | 3   | 1.47 |
| Discomfort at injection site | 0     | 0.00  | 2   | 0.98 |
| Soreness at injection site   | 5     | 14.71 | 3   | 1.47 |
| Pain at injection site       | 2     | 5.88  | 4   | 1.96 |
| Tightness                    | 0     | 0.00  | 2   | 0.98 |
| Knee Pain                    | 1     | 2.94  | 1   | 0.49 |
| Total adverse events         | 9     | 26.47 | 15  | 7.35 |




**Figure 1:** Numeric rating scale (NRS 0-10) pain evolution from baseline to 12 months follow up. Patients were asked: "What was your maximum pain in the past two weeks"? Differences between groups were statistically significant at all time points ( $p \leq 0.05$ ).




**Figure 2:** Numeric rating scale (NRS 0-10) pain evolution from baseline to 12 months follow up. Patients were asked: "What was your maximum pain in the past two weeks"? Differences between groups were statistically significant at all time points ( $p \leq 0.05$ ).



**Figure 3:** Western Ontario and McMaster Universities Arthritis Index (WOMAC) evolution from baseline to 12 months follow up. WOMAC global improvement of 36% was defined as clinically relevant. This target was reached for DEXA treated knees at month 12 and for ACS treated knees at months 3, 6 and 12. Note: here, the WOMAC global score ranges from 0-240. In this graph, the vertical axis is truncated at 120. Differences between groups were statistically significant at all time points ( $p \leq 0.05$ ).



**Figure 4:** GPA1. Patients were asked: “How would you assess the effectiveness of your osteoarthritis treatment at the present time?” Patients chose between improvements: poor, unsatisfactory, satisfactory, sufficient, good and very good.



**Figure 5:** GPA2. Patients were asked: “How much has the therapy helped your disease?” Answers were given in per cent (%).

## Discussion

### Limitations

Important limitations of this study are retrospective analysis, the small number of patients and the asymmetry of the treatment protocols due to the treatment in 2005. The higher number of injections of ACS vs one in the Dexa knees may have biased the outcomes. Also, the bilateral knee treatment may have influenced the patients' scoring of the respective knees. Baseline scores NRS, WOMAC pain and WOMAC global were statistically significant better in the Dexa group. >60% of patients were KL grade I and none were grade IV. Finally, the extent of pain medication and use of physical therapy of each patient was not quantitated, but possibly would not have affected outcome since it would have had effect on both knees.

## Key Results

In this cohort of patients with bilateral knee osteoarthritis injection of 6 doses ACS in one knee produces statistically significant better outcomes than one injection of Dexamethasone in the contralateral knee.

## Interpretation and Generalizability

In studies performed elsewhere ACS has been compared to placebo, Hyaluronan (HA), platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), ozone, dextrose prolotherapy, and glucocorticoid [24-33,37,39,41,42,44-46,49]. The authors of this current paper compared a standard routine of Dexa (5mg, one time) injection against an established protocol of ACS injection (6 injections of 2mL serum) in bilateral OA knees with K&L grade I to III changes. Dexa has been favorably evaluated for inflammation-

induced posttraumatic joint injury, preventing cartilage damage [65]. Data for ACS presented here confirm results by other groups with significant score improvements in RCT and non-RCT studies [17-27,29-35,37-49]. An exception is Yang et al. who reported weaker outcomes when ACS was compared to placebo [27]. Local injection with ACS has also shown significant benefit in other orthopedic and non-orthopedic indications, including back pain, tendinopathy, muscle injury, wound healing, meniscal pain and post-surgical treatment of ACL-reconstructed knees [34,35,37-49].

To put these results in perspective: Khurana et al. compared PRP (processed by laboratory protocol) to HA (Synvisc-one), depot-Methylprednisolone (depot), and a matched ACS cohort with follow up at 6 months.<sup>25</sup> They conclude that intra-articular injections of ACS and PRP are superior to HA and steroids in terms of clinical outcomes. Between PRP and ACS the difference by VAS and WOMAC (ES 0.41 and 0.82) was in favor of ACS. Notably, the small response rate in the depot group at 6 months contrasts with our finding of 34% pain relief at 6 months in the present manuscript. In perspective, “placebo effects” of up to 35% primary score improvement have been reported in other intra-articular injection studies and were considered valid, sometimes reaching large effect sizes for invasive (e.g. injections) OA treatments [65-70].

Glucocorticoid injections for more than four times annually are generally not recommended [52]. McAlindon, et al. showed that Triamcinolone 40mg, injected 4 times annually, led to a significant decrease of i.a. cartilage volume after 2 years. The authors confirmed that intra-articular injections of Triamcinolone should be used prudently [71]. Some authors have criticized McAlindon’s protocol since Triamcinolone (40mg) is mainly indicated “to tide over” an inflammatory episode and not as a regular OA injection therapy independent of symptoms [72]. In the current study the authors used only one injection of 5mg Dexamethasone.

It is commonly acknowledged that glucocorticoids have a transient symptomatic effect for up to 6 weeks on osteoarthritic joints [52]. Data in this study show a prolonged clinical effect of up to 12 months. Patients were treated in a clinical setting with easy access to hydrotherapy and physical therapy. The continued effect of steroid injection at 12 months after injection may be partly explained by the devotion of patients to daily knee exercise regimen, hydrotherapy, physical therapy, and the use of cryotherapy. Basella and Hernandez have described very good (ES >5) clinical results when patients enjoyed 30 sessions of intensive physiotherapy after 4 ACS injections [23]. This finding supports the consensus on physical therapy for OA patients. Knee stiffness improvement, in our study, was between 30% and 67%. This might also be due to daily knee exercise regimens. However, such activities were not quantitated.

Another explanation for the prolonged effect of glucocorticoid in this study might be a possible effect of ACS on the contralateral knee, possibly through a neurologic mechanism. Physical interventions in humans and biological (gene) therapy in animal experiments have produced evidence for a contralateral effect affecting clinical symptoms in a non-treated limb or organ [73-79]. ACS might have supported the glucocorticoid effect on the contralateral knee. Creamer compared the effects of intra-articular bupivacaine

injection versus placebo. With his small sample size (N=10 in each group), the contralateral non-injected knee had decreased pain at 7 days after injection in the bupivacaine group [80]. However, the placebo group did not have any reduction of pain in either knee, therefore, the study failed to detect a placebo effect. He attributed the reduction of knee pain to the release of neurotransmitters by the synovium, which in turn synapsed with afferent neuroreceptors of the contralateral knee in the spine.

In transgenic studies, contralateral joint effects have been attributed to transduced leukocytes, circulating transgenic product or immunomodulatory effect of circulating transduced dendritic cells [81]. In Brandt’s randomized study comparing intra-articular HA injection to saline, he did not notice any contralateral effect of either group [82]. In fact, he noticed an actual increase in pain in the contralateral knees of both groups at 27 weeks after injection. Kim et al. discussed that exosomes produced by dendritic cells may account for a positive contralateral effect, representing a novel, cell-free agent influencing immune dysfunction [79]. Incidentally, extracellular vesicles including exosomes are a common component in body fluids, plasma or serum, including ACS.

Osteoarthritis symptoms are not well understood. Cartilaginous changes at times do not correlate well with pain and dysfunction while inflammation and changes in synovium and/or bone may do so [83-86]. Dexamethasone is a potent and fast acting anti-inflammatory agent, ACS is thought to have a slower, more profound effect. The high number of 6 injections in the ACS knees is cumbersome but is in line with references 27 and 29. However, successful ACS treatment regimens with smaller numbers of injections (minimum 3) and smaller volumes (minimum 1mL) of injected serum have been published [18,23]. With regards to other Orthobiologics’ safety and reproducibility, ACS has advantages over the popular autologous platelet-rich plasma (PRP) for orthopedic indications.<sup>13,32</sup> ACS quality depends on the starting conditions (e.g., blood cell counts) and standardized extended coagulation conditions. ACS profoundly improves intra-articular homeostasis improving oxidative stress, and both cytokine balance IL-1Ra over IL-1b and autogenous Hyaluronic Acid content [13]. Interestingly, a recent study with i.a. PRP-resistant knee OA patients showed that  $\pm 2/3$  responded well to i.a. ACS injection [22]. Shirokova, et al. compared 6 injections of ACS or PRP in a prospective, non-randomized, open-label study and found that at the 3-month follow-up, clinical efficacy (VAS and WOMAC) improved significantly for both groups, but ACS had a more significant reduction from baseline to 3 months [13]. Furthermore, between the one-and three-month follow-up, ACS efficacy further increased, whereas PRP efficacy decreased. PRP did have a positive clinical effect in joints with “subclinical synovitis” (not inflamed), while joints with “moderate synovitis” (inflamed) did not have a clinical effect. This was the first study to investigate the biochemical effects of ACS vs PRP. Synovial fluid viscosity improved significantly more with ACS than in the PRP group. Cytokines IL-1Ra and IL-1b ratio was significantly stronger in the ACS group than in the PRP group. The authors concluded that ACS was clinically and biochemically superior to PRP and met the Minimal Clinically Important Improvement (MCII) criteria for VAS in knee OA. Adverse events with intra-articular PRP injections have been reported [87,88], however, in many PRP studies, adverse

events are briefly described as “self-resolving” and “transient”. This lack of detail in reporting is common and, frankly, disquieting. It appears that a PRP-related flare that may take up to a week to resolve is accepted as part of the treatment. Stanford Medical Center has a clear statement that 1 in 10 patients experience a flare with intense pain [accessed 2023-01-27 [89] The Integrative Medicine Center of Western Colorado mentions 1 in 20 patients with post-injection flare that resolves within “a few days” [90]. A literature search identified papers that describe possible mechanistic reasons for such caveats [87-103].

## Conclusion

The authors conclude that in this study ACS treatment is clinically significant more potent than Dexamethasone. Both ACS and Dexamethasone are safe and effective for intra-articular treatment of grade I to III bilateral knee OA. The clinical efficacy of Dexamethasone injections was unexpectedly long.

## Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

## Declaration of Conflict of Interest

NH, JL and DH declare no conflict of interest in preparing this article. JR works with Dr. Wehling & Partner, Germany.

## References

- Palmer JS, Monk AP, Hopewell S (2019) Surgical interventions for symptomatic mild to moderate knee osteoarthritis. *Cochrane Database Syst Rev* 7(3): CD012128.
- Osteoarthritis: A serious disease, submitted to the U.S. Food and Drug Administration, 2016 December. OARSI Report 2016.
- Leopoldino AO, Machado GC, Ferreira PH (2019) Paracetamol versus placebo for knee and hip osteoarthritis. *Cochrane Database Syst Rev* 2(2): CD013273.
- McAlindon TE, Bannuru RR, Sullivan MC (2014) OARSI guidelines for the non-surgical management of knee osteoarthritis. *Osteoarthritis Cartilage* 22(3): 363-88.
- Toupin April K, Barton JL, Fraenkel L (2019) OMERACT development of a core domain set of outcomes for shared decision-making interventions. *J Rheumatol* 46(10): 1409-1414.
- Goldring MB (2000) Osteoarthritis and cartilage: The role of cytokines. *Curr Rheumatol Rep* 2(6): 459-65.
- Lepetsos P, Papavassiliou AG (2016) ROS/oxidative stress signaling in osteoarthritis. *BBA - Molecular Basis of Disease* 2016; 1862(4): 576-591.
- Poulet B, Beier F (2016) Targeting oxidative stress to reduce osteoarthritis. *Arthritis Res Ther* 18: 32.
- Blanco F, Rego I, Ruiz Romero C (2011) The role of mitochondria in osteoarthritis. *Nat Rev Rheumatol* 7: 161-169.
- Pujol JP, Loyau G (1987) Interleukin-1 and osteoarthritis. *Life Sci* 41(10): 1187-1198.
- Cohen SB, Strand V, Aguilar D (2004) Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (Anakinra) therapy. *Rheumatology* 43(6): 704-711.
- Meijer H, Reinecke J, Becker C (2003) The production of anti-inflammatory cytokines in whole blood by physico-chemical induction. *Inflamm Res* 52(10): 404-407.
- Shirokova L, Noskov S, Gorokhova V (2020) Intra-articular injections of a whole blood clot secretome, autologous conditioned serum, have superior clinical and biochemical efficacy over platelet-rich plasma and induce rejuvenation-associated changes of joint metabolism: A prospective, controlled open-label clinical study in chronic knee osteoarthritis. *Rejuvenation Res* 23(5): 401-410.
- Wehling P, Moser C, Frisbie DD (2007) Autologous conditioned serum in the treatment of orthopedic diseases. The Orthokine therapy. *BioDrugs* 21(5): 323-332.
- Jansen T, Daiber A (2012) Direct antioxidant properties of bilirubin and biliverdin. Is there a role for biliverdin reductase? *Front Pharmacol* 3:30.
- Gazzin S, Vitek L, Watchko J (2016) A novel perspective on the biology of bilirubin in health and disease. *Trends Mol Med* 22(9): 758-768.
- Baltzer AWA, Drever R, Granrath M (2003) Intraarticular treatment of osteoarthritis using autologous interleukin-1 receptor antagonist (IL-1Ra) conditioned serum [german]. *Dtsch Z Sportmed* 54(6): 209-211.
- Motaal FKA, Elganzoury AM, Fathalla MM (2014) Low-dose intra-articular autologous conditioned serum in treatment of primary knee osteoarthritis. *Egypt Rheumatol Rehabil* 41:98-102.
- Tassara M, De Ponti A, Barzizza L (2018) Autologous conditioned serum (ACS) for intra-articular treatment in Osteoarthritis: Retrospective report of 28 cases. *Transfusion and Apheresis Science* 57(4): 573-577.
- Kılınc BE, Öc Y (2019) Evaluation of the autologous conditioned serum in the treatment of osteoarthritis. *Arch Clin Exp Med* 4(2): 94-98.
- Vitali M, Ometti M, Drossinos A (2020) Autologous conditioned serum: clinical and functional results using a novel disease modifying agent for the management of knee osteoarthritis. *J Drug Assess* 9(1): 43-51.
- Leone R, DeRosa A, Iudicone P (2021) Pain control and functional improvement in patients treated by autologous conditioned serum after failure of platelet rich plasma treatments in knee osteoarthritis. *Transfus Med* 31(5): 357-364.
- Baselga García Escudero J, Miguel Hernández Trillos P (2015) Treatment of osteoarthritis of the knee with a combination of autologous conditioned serum and physiotherapy: A two-year observational study. *PLoS One* 10(12): e0145551.
- Hussein M, Van Eck CF, Velikonja NK (2021) Bone marrow aspirate concentrate is more effective than hyaluronic acid and autologous conditioned serum in the treatment of knee osteoarthritis: A retrospective study of 505 consecutive patients. *Appl Sci* 11(7): 2932.
- Khurana A, Goyal A, Kirubakaran P (2020) Efficacy of autologous conditioned serum (ACS), platelet-rich plasma (PRP), hyaluronic acid (HA) and steroid for early osteoarthritis knee: A comparative analysis. *Indian J Orthop* 55(Suppl 1): 217-227.
- Coşkun HS, Yurtbay A, Say F (2022) Platelet rich plasma versus autologous conditioned serum in osteoarthritis of the knee: Clinical results of a five-year retrospective study. *Cureus* 14(4): e24500.
- Yang KGA, Rajmakers NJ, Van Arkel ER (2008) Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. *Osteoarthritis Cartilage* 16(4): 498-505.
- Rutgers M, Creamers LB, Yang KGA (2015) Osteoarthritis treatment using autologous conditioned serum after placebo. *Acta Orthop* 86(1): 114-118.
- Baltzer AWA, Moser C, Jansen SA (2009) Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. *Osteoarthritis Cartilage* 17(2): 152-160.
- Hashemi M, Taheri M, Adlkhoo H (2019) Comparison of the effect of intra-articular injection of autologous (Orthokine) interleukin-1 receptor antagonist (IL-1Ra) and hyaluronic acid in pain control of knee osteoarthritis. *Novel Biomed* 7(4): 210-217.
- Hashemi M, Adlkhoo H, Dadkhah P (2020) A comparative assessment of autologous conditioned serum and zone for knee osteoarthritis treatment: Mid-term follow up. *Novelty Biomed* 8(1): 45-52.
- Pishgahi A, Abolhasan R, Shakouri SK (2020) Effect of dextrose prolotherapy, platelet rich plasma and autologous conditioned serum on knee osteoarthritis: A randomized clinical Trial. *Iran J Allergy Asthma Immunol* 19(3): 243-252.

33. Baltzer AW, Ostapczuk MS, Stosch D (2013) A new treatment for hip osteoarthritis: clinical evidence for the efficacy of autologous conditioned serum. *Orthop Rev* 5(2): 59-64.
34. Cortegiani A, Ippolito M, Spurio G (2022) Use of autologous conditioned serum (ACS-ORTHOKINE) for osteoarthrosic chronic pain and facet joint syndrome: a prospective observational study. *Qeios*.
35. Simon MJK, Aartsen VE, Coghlan JA (2021) Shoulder injections with autologous conditioned serum reduce pain and disability in glenohumeral osteoarthritis: longitudinal observational study. *ANZ J Surg* 91(4): 673-679.
36. Wehling P, Cleveland SJ, Heininger K (1996) Neurophysiologic changes in lumbar nerve root inflammation in the rat after treatment with cytokine inhibitors. Evidence for a role of interleukin-1. *Spine* 21(8): 931-935.
37. Becker C, Heidersdorf S, Drewlo S (2007) Efficacy of epidural perineural injections with autologous conditioned serum for lumbar radicular compression. An investigator-initiated, prospective, double-blind, Reference-Controlled Study. *Spine* 32(17): 1803-1808.
38. H S RK, Goni VG, Y K B (2015) Autologous conditioned serum as a novel alternative option in the treatment of unilateral lumbar radiculopathy: A prospective study. *Asian Spine J* 9(6): 916-22.
39. Goni VG, Singh Jhala S, Gopinathan NR (2015) Efficacy of epidural perineural injection of autologous conditioned serum in unilateral cervical radiculopathy: A pilot study. *Spine* 40(16): E915-921.
40. Godek P (2016) Use of autologous serum in treatment of lumbar radiculopathy pain. Pilot study. *Ortop Traumatol Rehabil* 18(1): 11-20.
41. Von Wehren L, Pokorny K, Blanke F (2019) Injection with autologous conditioned serum has better clinical results than eccentric training for chronic Achilles tendinopathy. *Knee Surg Sports Traumatol Arthrosc* 27(9): 2744-2753.
42. Damjanov N, Barac B, Colic J (2018) The efficacy and safety of autologous conditioned serum (ACS) injections compared with betamethasone and placebo injections in the treatment of chronic shoulder joint pain due to supraspinatus tendinopathy: a prospective, randomized, double-blind, controlled study. *Med Ultrason* 20(3): 335-341.
43. Ipek D, Çalbiyık M, Zehir S (2022) Intratendinous injection of autologous conditioned serum for treatment of lateral epicondylitis of the elbow: A pilot study. *Arch Iran Med* 25(5): 319-323.
44. Darabos N, Hundric Haspl Z, Haspl M (2009) Correlation between synovial fluid and serum IL-1beta levels after ACL surgery-preliminary report. *Int Orthop* 33(2): 413-418.
45. Darabos N, Haspl M, Moser C (2011) Intraarticular application of autologous conditioned serum (ACS) reduces bone tunnel widening after ACL reconstructive surgery in a randomized controlled trial. *Knee Surg Sports Traumatol Arthrosc* 19(Suppl 1): S36-46.
46. Wright Carpenter T, Klein P, Schäferhoff P (2004) Treatment of muscle injuries by local administration of autologous conditioned serum: a pilot study on sportsmen with muscle strains. *Int J Sports Med* 25(8): 588-593.
47. Strümper R (2017) Intra-articular injections of autologous conditioned serum to treat pain from meniscal lesions. *Sports Med Int Open* 1(6): E200-205.
48. Strümper RW, Reinecke J, Rechmeier JW (2021) A combination of tissue glue and Orthokine ACS improves knee meniscus injury treatment and helps avoid surgery 4-year follow-up archive study. *Sports Injr Med* 5(1):1-8.
49. Gholian S, Pishgahi A, Shakouri SK (2022) Use of autologous conditioned serum dressings in hard-to-heal wounds: a randomised prospective clinical trial. *J Wound Care* 31(1): 68-77.
50. Gaffney K, Ledingham J, Perry JD (1995) Intra-articular triamcinolone hexacetonide in knee osteoarthritis: factors influencing the clinical response. *Ann Rheum Dis* 54(5): 379-381.
51. Friedman D, Moore M (1980) The efficacy of intra-articular steroids in osteoarthritis: a double-blind study. *J Rheumatol* 7(6): 850-856.
52. Bannuru RR, Osani MC, Vaysbrot EE (2019) OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. *Osteoarthritis Cartilage* 27(11): 1578-1589.
53. Permuy M, Guede D, López Peña M (2015) Effects of diacerein on cartilage and subchondral bone in early stages of osteoarthritis in a rabbit model. *BMC Vet Res* 11:143.
54. Miltner O, Schneider U, Siebert CH (2002) Efficacy of intraarticular hyaluronic acid in patients with osteoarthritis--a prospective clinical trial. *Osteoarthritis Cartilage* 10(9): 680-686.
55. Rabago D, Patterson JJ, Mundt M (2013) Dextrose prolotherapy for knee osteoarthritis: a randomized controlled trial 406 [published correction appears in *Ann Fam Med*. 11(5): 480]. *Ann Fam Med* 2013; 11(3): 229-237.
56. Stoker AM, Cook JL, Kuroki K (2006) Site-specific analysis of gene expression in early osteoarthritis using the Pond-Nuki model in dogs. *J Orthop Surg Res* 1:8.
57. Murat N, Karadam B, Ozkal S (2007) Şiçanlarda papainle oluşturulan osteoartrit Mankin skoru ile zamana bağlı derecelendirilmesi [Quantification of papain-induced rat osteoarthritis in relation to time with the Mankin score]. *Acta Orthop Traumatol Turc* 41(3): 233-237.
58. Lee SJ, Lee BS, Kim JM (2015) Clinical results of contralateral arthroscopic meniscectomy performed with unilateral total knee arthroplasty: Minimum 3-year follow-up. *Knee Surg Relat Res* 27(2): 76-81.
59. Jones MH, Spindler KP, Fleming BC (2015) Meniscus treatment and age associated with narrower radiographic joint space width 2-3 years after ACL reconstruction: data from the MOON onsite cohort. *Osteoarthritis Cartilage* 23(4): 581-588.
60. Marshall KW, Manolopoulos V, Mancor K (2000) Amelioration of disease severity by intraarticular hylan therapy in bilateral canine osteoarthritis. *J Orthop Res* 18(3): 416-425.
61. Sadeghi A, Esmaeilzadeh A, Lakzaei T (2021) A within-person, between-knee comparison of intra-articular platelet-rich plasma versus placebo injection in knee osteoarthritis: a randomized, double-blind comparison. *Res Sq Prepr* 1-14.
62. Pretorius J, Nemat N, Alsayed A (2022) Double-Blind Randomized Controlled Trial Comparing Platelet-Rich Plasma With Intra-Articular Corticosteroid Injections in Patients With Bilateral Knee Osteoarthritis. *Cureus*. 14(9).
63. Kellgren JH, Lawrence JS (1957) Radiological assessment of osteoarthritis. *Ann Rheum Dis* 16(4): 494-502.
64. Goldsmith CH, Boers M, Bombardier CP (1993) Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. *J Rheumatol* 20(3): 561-565.
65. Grodzinsky AJ, Wang Y, Kakar S (2017) Intra-articular dexamethasone to inhibit the development of post-traumatic osteoarthritis. *J Orthop* 453 Res35(3): 406-411.
66. Chevalier X, Goupille P, Beaulieu AD, Burch FX (2009) Intra-articular injection of Anakinra in osteoarthritis of the knee: A multicenter, randomized, double-blind, placebo-controlled study. *Arthritis Rheum* 61(3): 344-352.
67. Bar Or D, Salottolo KM, Loose H (2014) A randomized clinical trial to evaluate two doses of an intra-articular injection of LMWF-5A in adults with pain due to osteoarthritis of the Knee. *PLoS ONE* 9(2): 462 e87910.
68. Karlsson J, Sjögren LS, Lohmander LS (2002) Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double blind, parallel-design multicentre study. *Rheumatology* 41(11): 1240-1248.
69. Zhang W, Robertson J, Jones AC (2008) The placebo effect and its determinants in osteoarthritis: Meta-analysis of randomized controlled trials. *Ann Rheum Dis* 67(12): 1716-1723.
70. Saltzman BM, Leroux T, Meyer MA (2017) The therapeutic effect of intra-articular normal saline injections for knee 472 osteoarthritis: A meta-analysis of evidence level 1 studies. *Am J Sports Med* 45(11): 2647-2653.

71. McAlindon TE, LaValley MP, Harvey WF (2017) Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis. *JAMA* 317(19): 1967-1975.
72. Luijsterburg PAJ, Bos PK, Bierma Zeinstra SMA (2017) Long-term Intra-articular Steroid Injections and Knee Cartilage. *JAMA* 318(12): 1184.
73. Radhakrishnan R, Moore SA, Sluka KA (2003) Unilateral carrageenan injection into muscle or joint induces chronic bilateral hyperalgesia in rats. *Pain* 104(3): 567-577.
74. Shenker N, Haigh R, Roberts E (2003) A review of contralateral responses to a unilateral inflammatory lesion. *Rheumatology* 42(11):1279-1286.
75. Jortikka MO, Inkinen RI, Tammi MI (1997) Immobilisation causes long lasting matrix changes both in the immobilised and contralateral joint cartilage. *Ann Rheum Dis* 56(4): 255-483.
76. Carroll TJ, Herbert RD, Munn J (2006) Contralateral effects of unilateral strength training: evidence and possible mechanisms. *J Appl Physiol* 101(5): 1514-1522.
77. Stromberg BV (1986) Contralateral therapy in upper extremity rehabilitation. *Am J Phys Med* 65(3): 135-143.
78. Burstein H (2008) Intraarticular vector delivery for inflammatory joint disease. *Concepts in Genetic Medicine* (Eds Boro Dropulic and Barrie Carter), Wiley & Sons Page 137-144.
79. Kim SH, Lechman ER, Bianco N (2005) Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. *J Immunol* 174(10): 6440-6448.
80. Creamer P, Hunt M, Dieppe P (1996) Pain mechanisms in osteoarthritis of the knee: effect of intraarticular anesthetic. *J Rheumatol* 23(6): 1031-1036.
81. Ghivizzani SC, Lechman ER, Kang R (1998) Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritis effects. *Proc Natl Acad Sci USA* 95(8): 4613-4618.
82. Brandt KD, Smith GN, Simon LS (2000) Intraarticular injection of hyaluronan as treatment for knee osteoarthritis: what is the evidence? *Arthritis Rheum* 43(6): 1192-1203.
83. Neogi T, Niu J, Felson D (2009) Association between radiographic features of knee osteoarthritis and pain: results from two cohort studies. *BMJ* 339: b2844.
84. Bedson J, Croft PR (2008) The discordance between clinical and radiographic knee osteoarthritis: A systematic search and summary of the literature. *BMC Musculoskeletal Disord* 9: 116.
85. Wu PT, Shao CJ, Wu KC (2012) Pain in patients with equal radiographic grades of Osteoarthritis in both knees: the value of gray scale ultrasound. *Osteoarthritis Cartilage* 20(12): 1507-1513.
86. Ashraf A, Jali R, Fakheri M (2014) Correlation between functional status and thickness of articular cartilage in ultrasonography in patients with knee osteoarthritis. *J PMR Sci* 17: 64-67.
87. Kaux JF, Croisier JL, Léonard P (2013) Exuberant inflammatory reaction after an infiltration of platelet-rich plasma (PRP). *Br J Sports Med* 47(10): e3.
88. Filardo G, Di Matteo B, Di Martino A (2015) Platelet-rich plasma intra-articular knee Injections show no superiority versus viscosupplementation. A randomized controlled trial. *Am J Sports Med* 43(7): 1575-1582.
89. Stanford University Medical Center. Department of Radiology. Platelet Rich Plasma (PRP) Injection - Information and Instructions for Patients, page 3 paragraph 1.
90. Integrative Medicine Center of Western Colorado. Aftercare Instructions for Platelet Rich Plasma Injections.
91. Lindemann S, Tolley ND, Dixon DA (2001) Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. *J Cell Biol* 154(3):485-490.
92. Hottz ED, Monteiro APT, Bozza FA (2015) Inflammasome in platelets: Allying coagulation and inflammation in infectious and sterile diseases? *Mediators Inflamm* Article ID 435783.
93. Boilard E, Nigrovic PA, Larabee K (2010) Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. *Science* 327(5965): 580-583.
94. Boilard E, Larabee K, Shnayder R (2011) Platelets participate in synovitis via Cox-1- dependent synthesis of prostacyclin independently of microparticle generation. *J Immunol* 186(7): 4361-4366.
95. Nurden AT (2011) Platelets, inflammation and tissue regeneration. *Thromb Haemost* 105(Suppl 1): S13-33.
96. Conde ID, Cruz MA, Zhang H (2005) Platelet activation leads to activation and propagation of the complement system. *J Exp Med* 201(6):871-879.
97. Kelly JC (2011) Complement cascade leads to OA damage. *Medscape Medical News* November Page 1-2.
98. Wang Q, Rozelle AL, Lepus CM (2011) Identification of a central role for complement in osteoarthritis. *Nat Med* 17(12): 1674-1679.
99. Peerschke IB, Yin, Ghebrehiet B (2008) Platelet mediated complement activation. *Adv Exp Med Biol* 632:81-91.
100. Peerschke EIB, Yin W, Grigg SE (2006) Blood platelets activate the classical pathway of human complement. *J Thromb Haemost* 4(9): 2035-2042.
101. Hamad OA, Ekdahl KN, Nilsson PH (2008) Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. *J Thromb Haemost* 6(8): 1413-1421.
102. Smiley ST, King JA, Hancock WW (2001) Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. *J Immunol* 167(5): 2887-2894.
103. Flick MJ, LaJeunesse CM, Talmage KE (2007) Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin  $\alpha$ MP2 binding motif. *J Clin Invest* 117(11): 3224-3235.
104. Cohen JA (1992) power primer. *Psychol Bull.* 112(1):155-159.
105. Matzkin EG, Curry EJ, Kong Q (2017) Efficacy and Treatment Response of Intra-articular Corticosteroid Injections in Patients With Symptomatic Knee Osteoarthritis. *J Am Acad Orthop Surg.* 25(10):703-714.




This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here:

[Submit Article](#)

DOI: [10.32474/OSMOAJ.2023.06.000236](https://doi.org/10.32474/OSMOAJ.2023.06.000236)



### Orthopedics and Sports Medicine Open Access Journal Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles